Abstract
Thirty-six patients with previously treated low-grade non-Hodgkin's lymphoma (LG-NHL) were included in a phase II study between August 1990 and February 1994 and treated with 0.12 mg/kg CdA as a 2 h.i.v. infusion daily x V, q 28 days up to 6 courses. Twenty-three were refractory to previous chemotherapy while 13 were relapsed. Four patients had mantle cell lymphoma, 17 follicle centre cell derived lymphoma, 7 lymphoplasmacytoid lymphomas and, 8 had small lymphocytic lymphoma. The response rate was 42%, with 5 (14%) CR and 10 (28%) PR while 6 (16%) patients progressed during treatment. The median number of delivered CdA courses was 3 (1-6) in non-responding cases and 6 (2-6) in responders. The median time to progression was 9 mo for all patients, 23 mo for CR and 16 mo for PR patients. Toxicity was sometimes severe with 3 infectious deaths (1 pneumocystis carinii pneumonia, 1 gram negative septicemia, and 1 fungal pneumonia), and 6 grade 3 or 4 infectious episodes. We conclude that responses to CdA in this group of heavily pre-treated patients is impressive. However, toxicity is considerable and the rate of opportunistic infections is worrisome.
References
Mar 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M SantanaR L Blakley
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C KayL D Piro
Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J LiliemarkG Juliusson
Nov 1, 1992·Investigational New Drugs·S Green, G R Weiss
Apr 19, 1990·The New England Journal of Medicine·L D PiroE Beutler
Jul 1, 1972·Journal of Medicinal Chemistry·L F ChristensenA Bloch
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D Cheson
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonG Tjønnfjord
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Jul 2, 1994·Lancet·J C SipeE Beutler
Jan 1, 1993·British Journal of Cancer·T HickishA Roldan
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Juliusson, J Liliemark
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonJ Liliemark
Jan 1, 1991·Leukemia & Lymphoma·A SavenL D Piro
Citations
Aug 26, 1998·Leukemia & Lymphoma·J LiliemarkG Juliusson
Jul 17, 2010·Blood·Darren S SigalAlan Saven
May 13, 2009·Cancer Science·Kensei TobinaiYasuo Ohashi
Jul 24, 2014·Clinical Lymphoma, Myeloma & Leukemia·Annete NjueFarrukh Awan
Aug 10, 2005·Chemotherapy·T RobakK Chojnowski
Jun 24, 2000·Leukemia·E Van Den NesteA Ferrant
Nov 23, 2006·Cancer·Kristie A BlumUNKNOWN Cancer and Leukemia Group B Study 9153
Sep 2, 2006·Cancer·Tadeusz RobakJerzy Z Blonski
Oct 8, 1999·Leukemia & Lymphoma·M J RummelP S Mitrou
Apr 12, 2008·Expert Review of Anticancer Therapy·Darren S Sigal, Alan Saven
Nov 13, 2009·Journal of Clinical and Experimental Hematopathology : JCEH·Yasushi TakamatsuKazuo Tamura
May 15, 2001·European Journal of Haematology·T RobakM Kasznicki
Jun 20, 2007·Leukemia & Lymphoma·Tadeusz RobakJoanna Gora-Tybor
Dec 7, 2002·Best Practice & Research. Clinical Haematology·Pier Luigi Zinzani